Crestor vs Leqvio Side Effects: Rosuvastatin vs Inclisiran Head-to-Head Safety Comparison

Why These Two Drugs Get Compared

Rosuvastatin and inclisiran occupy different pharmacologic classes but chase the same clinical target: lowering LDL cholesterol to reduce cardiovascular events. Rosuvastatin is a high-intensity statin that inhibits HMG-CoA reductase in the liver. Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 mRNA, allowing more LDL receptors to clear circulating LDL particles 1.

The comparison comes up most often in two scenarios. First, patients who cannot tolerate statin side effects (particularly myalgia) look to inclisiran as an alternative that avoids muscle toxicity. Second, patients already on a statin who need additional LDL reduction may add inclisiran rather than uptitrate. The 2022 ACC Expert Consensus Decision Pathway recommends non-statin agents, including PCSK9-targeted therapies, for patients with atherosclerotic cardiovascular disease (ASCVD) who remain above LDL goals despite maximally tolerated statin therapy 2. Because no randomized trial has directly compared the safety profiles of rosuvastatin and inclisiran, clinicians must synthesize evidence from JUPITER 3, ORION-10, ORION-11 1, and post-marketing surveillance.

Rosuvastatin (Crestor): Side-Effect Profile in Detail

Muscle symptoms are the defining tolerability issue with rosuvastatin and all statins. In JUPITER (N=17,802), myalgia was reported by a similar proportion of statin and placebo arms, but real-world registries consistently show that 5 to 10% of statin users report muscle complaints 4. Rhabdomyolysis, the severe end of the spectrum, occurs in roughly 1 per 10,000 patient-years on high-intensity statins.

Hepatic effects deserve attention. Rosuvastatin can raise ALT and AST, especially at the 40 mg dose. The FDA label recommends baseline liver function testing and repeat testing if clinically indicated 5. Clinically significant hepatotoxicity is rare, occurring in fewer than 1% of patients.

The diabetes signal is real. JUPITER showed a 27% relative increase in physician-reported diabetes among rosuvastatin users (3.0% vs 2.4% placebo, P=0.01) over a median 1.9-year follow-up 3. A 2010 meta-analysis of 13 statin trials (N=91,140) found a 9% increased risk of incident diabetes with statin therapy, with higher-intensity statins carrying greater risk 6.

Other reported effects include headache (5.5%), nausea (3.4%), proteinuria (dose-related, typically at 40 mg), and peripheral neuropathy (rare). Cognitive complaints ("brain fog") appear in post-marketing reports, though the HOPE-3 trial found no measurable cognitive decline over 5.6 years of rosuvastatin use 7.

Inclisiran (Leqvio): Side-Effect Profile in Detail

Injection-site reactions (ISRs) are the most frequently reported adverse event with inclisiran. Pooled data from ORION-10 (N=1,561) and ORION-11 (N=1,617) showed ISRs in 5% of inclisiran-treated patients versus 0.7% on placebo 1. These reactions were mild or moderate in all but 0.2% of cases, typically presenting as erythema, pain, or induration at the injection site. Most resolved within one to two days.

Nasopharyngitis, bronchitis, urinary tract infection, and back pain were reported at rates slightly above placebo in the ORION program. None of these exceeded a 5% absolute incidence. Headache occurred in 3.5% of inclisiran patients.

A key distinction: inclisiran shows no signal for myalgia, myopathy, or rhabdomyolysis. Because it works downstream of HMG-CoA reductase, skeletal muscle metabolism is unaffected. This makes it a pharmacologically logical option for patients with documented statin-associated muscle symptoms (SAMS) 8.

Liver safety data are reassuring. In pooled ORION analyses, the proportion of patients with ALT >3x the upper limit of normal was similar between inclisiran and placebo groups. No diabetes signal has emerged in ORION data through 18 months of follow-up, though longer observation is needed 1.

Muscle Symptoms: The Core Differentiator

Statin-associated muscle symptoms remain the single most common reason patients stop or refuse statin therapy. A real hard number: the STOMP trial (N=420) found that high-dose atorvastatin raised creatine kinase by an average of 20.8 IU/L compared to placebo, and 9.4% of statin users reported myalgia 9.

Inclisiran bypasses this problem entirely. Its mechanism (silencing hepatic PCSK9 via RNA interference) does not interact with the mevalonate pathway in muscle tissue. In the ORION-10 and ORION-11 trials, muscle-related adverse events occurred at rates indistinguishable from placebo 1. For patients who have failed two or more statins due to muscle complaints, inclisiran offers LDL reduction without the myotoxic liability.

The National Lipid Association's 2023 statin intolerance algorithm recommends rechallenge with a different statin at lower dose as the first step, followed by non-statin therapies including PCSK9 inhibitors or inclisiran if muscle symptoms recur 10. This positions inclisiran as a second-line or third-line agent after statin failure, not a first-line replacement.

Diabetes Risk: Statins vs siRNA

The metabolic cost of statins extends beyond muscle. JUPITER's diabetes finding was consistent with a class effect: a meta-analysis by Sattar et al. (2010) covering 91,140 participants across 13 trials calculated an odds ratio of 1.09 (95% CI 1.02 to 1.17) for new-onset diabetes with statin use 6. Higher potency statins like rosuvastatin carry a proportionally greater risk than lower-intensity agents.

Inclisiran has not shown any diabetes signal. Across the ORION clinical development program, fasting glucose and HbA1c levels remained stable in inclisiran-treated patients through 540 days of follow-up 1. The mechanism makes biological sense: PCSK9 silencing increases hepatic LDL receptor recycling without affecting insulin signaling pathways or glucose transporter expression in skeletal muscle.

A caveat is necessary. ORION follow-up periods (18 months in key trials) are shorter than JUPITER's (median 1.9 years, with some patients followed 5+ years). The absence of a diabetes signal with inclisiran may partly reflect limited exposure duration. ORION-4 (N=15,000, outcomes trial) will provide more definitive long-term metabolic safety data when results are reported.

Injection-Site Reactions vs Daily Pill Burden

The trade-off between these two drugs is, in practical terms, a trade-off between chronic daily side effects and intermittent procedural discomfort. Rosuvastatin requires daily dosing, meaning any side effect (muscle aches, GI symptoms, headache) persists as long as the patient takes the drug.

Inclisiran's twice-yearly dosing after the initial loading period (day 1, day 90, then every 6 months) concentrates adverse events around the injection visit. ISRs peak within 24 to 48 hours and resolve. Between injections, patients report no ongoing drug-related symptoms in the vast majority of cases.

For patients who value minimal daily interference, this dosing model is appealing. For those with needle phobia or limited access to a healthcare provider for in-office injection (inclisiran requires administration by a healthcare professional per the FDA label), the daily oral tablet may be preferable 11.

Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine, has noted: "The choice between a statin and a PCSK9-targeted therapy often comes down to individual tolerability. The best lipid-lowering drug is the one the patient will actually take consistently."

Drug Interactions and Special Populations

Rosuvastatin has a notable drug interaction profile. It is not extensively metabolized by CYP3A4 (unlike atorvastatin or simvastatin), which reduces some interaction risks. It is a substrate of OATP1B1 and BCRP transporters, so co-administration with cyclosporine, certain protease inhibitors, or gemfibrozil increases rosuvastatin exposure and toxicity risk 5. Asian-descent patients have 2-fold higher rosuvastatin exposure, and the FDA label recommends a starting dose of 5 mg in this population.

Inclisiran's interaction profile is minimal. As a siRNA, it is metabolized by nucleases into inactive nucleotides, not by hepatic CYP enzymes. No clinically significant drug-drug interactions have been identified 11. This is particularly relevant for patients on complex multi-drug regimens (transplant recipients, HIV patients on antiretrovirals, oncology patients) who need LDL lowering without adding interaction risk.

In renal impairment, rosuvastatin exposure increases with declining GFR, and the 40 mg dose is contraindicated in severe renal impairment. Inclisiran requires no dose adjustment in mild-to-moderate renal impairment; data in severe renal impairment (eGFR <30) are limited but show no significant pharmacokinetic changes 12.

Both drugs are contraindicated in pregnancy. Neither is recommended during breastfeeding.

Cost and Access Considerations

Side-effect discussions cannot be separated from cost, because cost determines whether a patient stays on therapy long enough to experience side effects or benefits. Generic rosuvastatin costs $10 to $30 per month at most U.S. pharmacies. Inclisiran carries a list price of approximately $3,250 per injection ($6,500 per year) 11.

Insurance coverage for inclisiran typically requires documentation of statin intolerance or inadequate LDL response on maximally tolerated statin therapy plus ezetimibe. Prior authorization is standard. Medicare Part B covers inclisiran as a physician-administered drug (it is given in-office, not self-injected), which can reduce out-of-pocket costs for eligible patients.

The economic imbalance means that for most patients with no statin intolerance, rosuvastatin remains the first-line choice despite its broader side-effect profile. Inclisiran's side-effect advantage becomes clinically actionable only when statin tolerability fails or additional LDL lowering is required beyond maximal statin plus ezetimibe.

Who Should Consider Switching

A patient on rosuvastatin experiencing persistent myalgia after dose reduction and statin switching (per NLA guidelines, at least two statin trials) is a candidate for inclisiran if their ASCVD risk warrants continued LDL lowering 10. The Endocrine Society's 2020 guidelines also support PCSK9-targeted therapy in patients with familial hypercholesterolemia who do not reach LDL targets on statins alone 13.

Patients tolerating rosuvastatin well, with LDL at goal, have no clinical reason to switch. Rosuvastatin has decades of cardiovascular outcomes data (JUPITER showed a 44% reduction in the composite primary endpoint of MI, stroke, revascularization, hospitalization for unstable angina, or CV death 3). Inclisiran's cardiovascular outcomes trial (ORION-4) has not yet reported, meaning its effect on hard endpoints (MI, stroke, death) remains unproven.

Dr. Steven Nissen, chief academic officer at the Cleveland Clinic Heart, Vascular, and Thoracic Institute, has stated: "We do not yet have outcomes data for inclisiran. LDL lowering is a validated surrogate, but confirmation from ORION-4 is essential before we can call these drugs equivalent in terms of event reduction."

Summary Table: Side-Effect Comparison

| Adverse Event | Rosuvastatin (Crestor) | Inclisiran (Leqvio) | |---|---|---| | Myalgia | 5 to 10% (real-world) | No signal above placebo | | Rhabdomyolysis | ~1 per 10,000 pt-years | Not reported | | Injection-site reaction | N/A (oral) | 5% in ORION trials | | New-onset diabetes | ~27% relative increase (JUPITER) | No signal (limited follow-up) | | ALT elevation >3x ULN | <1%, dose-dependent | Similar to placebo | | Headache | 5.5% | 3.5% | | GI symptoms | 3 to 5% | Not above placebo | | Drug interactions | Moderate (OATP1B1/BCRP substrates) | Minimal | | Renal dose adjustment | Yes (40 mg contraindicated in severe CKD) | Not required |

Patients starting or switching lipid-lowering therapy should have baseline liver function, creatine kinase (if symptomatic), HbA1c, and renal function measured. Rosuvastatin monitoring includes repeat LFTs at 12 weeks and CK if muscle symptoms develop. Inclisiran monitoring focuses on lipid panels at 90 days (after the second dose) and at each subsequent 6-month injection visit, with inspection of injection sites for delayed hypersensitivity 11.